{
    "organizations": [],
    "uuid": "5dee47aea2f410ae76b10b8ed7a3aef411fae039",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rhythm-pharma-announces-licensing/brief-rhythm-pharma-announces-licensing-agreement-with-takeda-idUSFWN1RF09H",
    "ord_in_thread": 0,
    "title": "BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Rhythm Pharmaceuticals Inc:\n* RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME\n* RHYTHM PHARMACEUTICALS INC - ‍RHYTHM EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION IN Q1 OF 2020​\n* RHYTHM PHARMACEUTICALS INC - ‍ ACQUIRED EXCLUSIVE, WORLDWIDE RIGHTS FROM TAKEDA TO DEVELOP AND COMMERCIALIZE T-3525770 (NOW RM-853)​\n* RHYTHM PHARMACEUTICALS INC - ‍UNDER TERMS, CO WILL ASSUME SOLE RESPONSIBILITY FOR GLOBAL PRODUCT DEVELOPMENT AND COMMERCIALIZATION OF RM-853​\n* RHYTHM PHARMACEUTICALS-‍ TAKEDA TO GET UPFRONT PAYMENT OF $5 MLN IN CO’S STOCK, BACK-END DEVELOPMENT MILESTONES, SINGLE-DIGIT ROYALTIES ON RM-853 SALES​\n* RHYTHM PHARMACEUTICALS INC - ‍WILL EXPLORE OPPORTUNITIES TO EVALUATE SETMELANOTIDE AND RM-853 IN COMBINATION, AS THERE MAY BE COMPLEMENTARY EFFECTS​​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-02T20:40:00.000+03:00",
    "crawled": "2018-04-03T16:19:28.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "rhythm",
        "pharmaceutical",
        "inc",
        "rhythm",
        "pharmaceutical",
        "announces",
        "licensing",
        "agreement",
        "takeda",
        "development",
        "commercialization",
        "preclinical",
        "treatment",
        "syndrome",
        "rhythm",
        "pharmaceutical",
        "inc",
        "expects",
        "file",
        "investigational",
        "new",
        "drug",
        "application",
        "q1",
        "rhythm",
        "pharmaceutical",
        "inc",
        "acquired",
        "exclusive",
        "worldwide",
        "right",
        "takeda",
        "develop",
        "commercialize",
        "rhythm",
        "pharmaceutical",
        "inc",
        "term",
        "co",
        "assume",
        "sole",
        "responsibility",
        "global",
        "product",
        "development",
        "commercialization",
        "rhythm",
        "takeda",
        "get",
        "upfront",
        "payment",
        "mln",
        "co",
        "stock",
        "development",
        "milestone",
        "royalty",
        "rhythm",
        "pharmaceutical",
        "inc",
        "explore",
        "opportunity",
        "evaluate",
        "setmelanotide",
        "combination",
        "may",
        "complementary",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}